返回新闻列表Back to News
药明合联与苏州佰睿壹达成战略技术合作，共同赋能下一代ADC创新研发
Global strategic technology collaboration with WUXI XDC
全球领先的生物偶联药物合同研究、开发与生产企业（CRDMO）药明合联（WuXi XDC，股票代码：2268.HK），今日宣布与专注于化学定点偶联技术创新的苏州佰睿壹生物技术有限公司（以下简称"佰睿壹"）达成战略技术合作，共同加速下一代抗体偶联药物的开发进程，推动行业技术革新。
根据合作协议，佰睿壹将提供自主研发的MCLICK化学定点偶联技术（涵盖DAR1、DAR2和DAR6），与药明合联将在全球独家CRDMO合作，药明合联将这些偶联技术融入其先进的ADC技术平台，借助其全球领先、一站式CRDMO服务平台，全面释放MCLICK技术的行业应用潜力，赋能客户。 WuXi XDC and Bio-Reinnovation strategic technology collaboration aimed at accelerating the development of next-generation ADCs.
BioReinno will provide its proprietary MCLICK chemical site-specific conjugation technologies—including DAR1, DAR2, and DAR6, to form global exclusive CRDMO collaboration with WuXi XDC.
WuXi XDC will leverage and integrate these advanced technologies into its "All-in-One" CRDMO platform and provide comprehensive research, development and manufacturing services to clients.
根据合作协议，佰睿壹将提供自主研发的MCLICK化学定点偶联技术（涵盖DAR1、DAR2和DAR6），与药明合联将在全球独家CRDMO合作，药明合联将这些偶联技术融入其先进的ADC技术平台，借助其全球领先、一站式CRDMO服务平台，全面释放MCLICK技术的行业应用潜力，赋能客户。 WuXi XDC and Bio-Reinnovation strategic technology collaboration aimed at accelerating the development of next-generation ADCs.
BioReinno will provide its proprietary MCLICK chemical site-specific conjugation technologies—including DAR1, DAR2, and DAR6, to form global exclusive CRDMO collaboration with WuXi XDC.
WuXi XDC will leverage and integrate these advanced technologies into its "All-in-One" CRDMO platform and provide comprehensive research, development and manufacturing services to clients.
药明合联与苏州佰睿壹达成战略技术合作，共同赋能下一代ADC创新研发
WuXi XDC and Bio-Reinnovation sign strategic technology collaboration for next-generation ADCs